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is fully funded by National Health System in Portugal since 2001. Since March 2013 
Portuguese electronic prescription system became more generalized, allowing 
central monitoring and validation of medicines prescription and dispensing. This 
database only contains medicines dispensing data in ambulatory setting. TTR-
FAP anonymized patient’s utilization was requested to Administração Central do 
Sistema Saúde(ACSS). International Non-proprietary Names (INN) were extracted 
from INFARMED medicines database. Total and mean annual costs per patient are 
reported in euros. Results: Over the year 2014, a total of 70 286 electronic dispens-
ing activities were imputed to 2013 TTR-FAP anonymized patients in ACSS data-
base. The total cost with TTR-FAP medicines dispensed in ambulatory setting was 
1 612 673 € . The mean annual cost per patient was 801 € (standard deviation 1 233 
€ ). ConClusions: We can conclude that Portuguese ACSS electronic prescription 
database is a useful, relevant and accessible strategy to estimate medicines expendi-
ture trough anonymized individual patient data. Access to additional individual 
patient data such as age/gender would enhance future studies. We can estimate 
that TTR-FAP disease in Portugal accounted for 1 612 673 € total cost in ambulatory 
medicines, with a mean annual cost per patient of 801 € .
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objeCtives: To describe the hospital stays of patients with systemic lupus erythe-
matosus (SLE) in Belgium during one calendar year. Methods: All adult patients 
having ≥ 1 stay with a primary or secondary diagnosis of SLE (ICD-9-CM code 710.0) 
in 2013 were retrieved from the longitudinal IMS Hospital Disease Database (HDD; 
capturing 24% of Belgian hospital beds). All stays generated by these patients 
during the year were retrieved with their characteristics (admission type, associ-
ated diagnoses, in-hospital mortality, length of stay, drugs, procedures, costs) and 
descriptive statistics were derived (mean +/- standard deviation or [interquartile 
range]). Correlation coefficients (Pearson, Spearman) were calculated between 
age, number of stays/patient, total length of stay/patient, annual cost/patient 
and the number of organ systems involved (estimated per patient, based on the 
ICD-9-CM codes of associated diagnoses, further classified into SLE-specific organ 
systems). Results: In 2013, 434 adult SLE patients were identified (82.0% female; 
mean age 54.8 +/- 17.0 years; mean 3.0 [2-4] organ systems involved distributed 
as follows: Musculoskeletal 97.9%, Circulatory/respiratory 54.4%, Mental/Nervous 
system 38.8%, Digestive 31.8%, Renal 29.0%, Haematologic 25.0%, Skin/subcuta-
neous tissue 15.4%, Ophthalmic 6.1%. The mean annual hospitalization cost/
patient was € 8,741 [1,715-9,533]). These patients generated 939 stays (2.2 [1-2] 
stays/patient; 29.7% unplanned admissions; 56.4% full hospitalizations with mean 
length of stay 8.4 days [2-9]). The in-hospital mortality was 2.2% and the mean 
total cost/stay was € 4,069 [366-4,202]). The number of organ systems involved was 
significantly (p< 0.001) correlated to age (Pearson/Spearman: 0.40/0.38), number 
of stays/patient (0.21/0.26), total length of stay (0.57/0.59) and annual cost/patient 
(0.53/0.55). ConClusions: The analysis of real-world hospitalization data showed 
how the burden and complexity of SLE management increases as the organ sys-
tems involvements accrue. Extrapolating the HDD data to the total Belgian popu-
lation, about 1,800 SLE patients might require hospital treatments every year, 
representing a substantial burden for patients and society.
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objeCtives: A myriad of valuation techniques are used by various healthcare 
system stakeholders to appraise drugs. The objective of this evaluation was to 
develop a systematic and evidence-based approach to appraising a drug’s rela-
tive performance. We developed a multi-attribute valuation methodology taking 
into account efficacy, safety and humanistic factors to synthesize relative value 
created by pharmaceutical interventions. We report on our findings for ten onco-
logic therapies. Methods: Health Technology Assessments (HTAs), published trial 
results, and publications archived in PubMed all between 2005 – 2013 were analyzed 
to identify key value attributes. The following five attributes were considered: a) 
Overall Survival (OS), b) Progression Free Survival (PFS), c) Route of Administration, 
d) Trial Comparator, and e) Adverse events. Based on outcomes from clinical tri-
als for each of those attributes for each drug analyzed, the performance of the 10 
oncologic therapies was measured on the selected attributes. We then generated an 
aggregate score for each drug. Drugs were then compared on value score vs. cost of 
treatment to understand the value-cost relationship. Results: The multi-attribute 
analysis and scoring exercise demonstrated that drugs with more than 3 months of 
OS benefit incremental to their clinical trial comparator had higher net value scores, 
whereas PFS without a complementary increment in OS did not significantly impact 
the value score of the drug. Based on a linear model we developed, drug prices 
increased approximately $170/month ($2040/year) for each month of OS improve-
ment. Larger samples will be required to confirm this correlation. ConClusions: 
The framework may be employed to assign a value “score” for cancer drugs that 
may help stakeholders to assess value versus cost of an oncology treatment. Further 
research is needed to compare and contrast this framework with ’other’s such as 
Memorial Sloan Kettering Cancer Center’s “Drug Abacus” framework.
PSY53
coST-effecTiveneSS of PonATiniB foLLowed BY STem ceLL TrAnSPLAnT 
verSuS BeST SuPPorTive cAre for uk PATienTS wiTh PhiLAdeLPhiA 
chromoSome-PoSiTive AcuTe LYmPhoBLASTic LeukAemiA AfTer fAiLure 
of dASATiniB
Iannazzo S1, Chiroli S2, Rowntree C3, McGarry L4, Briggs A5
in 2009: 73% of all costs, cumulatively 300.805,52 EUR (2009-2013). Total average costs 
for period of 5 years (2009-2013) per 1 patient was 48.884,01 EUR. Year-by-year aver-
age costs for 1 patient were as follows: in 2009 24.795 EUR, in 2010 4.682 EUR, in 2011 
3.273 EUR, in 2012 3.630 EUR and in 2013 12.456 EUR. Most influential cost factor was 
average hospitalization/1 patient that dramatically decreased between 2009 and 
2011 (16.651 EUR vs 2.009 EUR) and than increase between 2011 and 2013 (2.009 EUR 
vs 10.531 EUR). We also found negative significant statistical correlation between 
age of patients and costs. ConClusions: We performed first direct costs analysis 
in patients with CF in single center. More data are needed to be able to evaluate 
exact costs associated with CF treatment that should serve as solid background for 
decision making process at national level.
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objeCtives: To analyze the cost of treating invasive fungal infections (IFI) in stem cell 
transplant patients. Methods: Prospective observation cost study from the hospital 
point of view was performed in the major hematology clinic in Sofia for one year 
period. Bottom up cost analysis for the consumed health care resources and their 
cost was performed for all stem cell transplant patients. Medical resources included 
in the analysis was the clinical tests, medical devices, transplantation procedure, 
medicines, blood and blood formulating products, conditioning regime and cost of 
hospital stay. Cost of the resources was taken from the hospital tariff and insurance 
fund charges. Direct medical cost was calculated for the average transplant procedure 
and for the patients when IFI appears. Results: Every patent with hemopoietic stem 
cell transplantation is considered for highly risky for fungal infection appearing due 
to suppressed immune system. Antifungal prophylactic is obligatory for allogenic 
transplantation (n= 27) and for susceptible patients with autologues transplantation 
(n= 64). For allogenic transplantation prophylactic is performed with voriconazole and 
costs 3500 Euro. For the other patients usually fluconazole or itraconazole is used cost-
ing 1600 Euro. The total cost of allogenic transplantation from relative donor is 15000 
Euro, for allogenic transplantation from non-relative is 25000 Euro and for autologues 
transplantation is varying between 10-20 000 Euro. Despite of prophylactics 3 IFIs were 
recorded during one year period and the cost of therapy rise to 50 000 Euro mostly due 
to increase in medicines cost to 66% of total cost. ConClusions: The IFIs are twice 
increasing the average cost of hemopoietic stem cell transplantation mainly due to 
the increase in the cost of medicines to manage the infection.
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objeCtives: Published real-world studies suggest voriconazole may provide reduced 
length-of-stay, intravenous (IV) length-of-therapy (LOT), and costs compared to liposo-
mal amphotericin B (LAMB) and caspofungin in invasive aspergillosis (IA) patients. We 
performed a cost analysis of voriconazole versus LAMB and caspofungin as first-line 
antifungal treatment for IA among patients with prolonged neutropenia or undergo-
ing bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) from payer 
perspective in Kingdom of Saudi Arabia (KSA). Methods: A decision analytic model 
with a 6-week time horizon was constructed to estimate potential treatment cost of 
alternative interventions voriconazole, LAMB, and caspofungin. Each treatment path-
way was defined by probabilities of an event occurrence and costs (in US$) of clinical 
outcomes derived from published literature, clinical trials, and local expert opinions. 
Patients who failed first-line voriconazole were assumed to have a switch-to or add-on 
of caspofungin; patients who failed LAMB or caspofungin were assumed to have a 
switch-to or add-on of voriconazole. Base-case evaluation included drug management 
costs and additional hospitalization costs due to severe adverse events. Results: 
Based on the clinical trial treatment success rates of 52.8% for voriconazole, 50.0% for 
LAMB, and 33% for caspofungin, as well as assuming first-line 14-day IV treatment 
and 10-day oral treatment for voriconazole, 24-day IV treatment for LAMB, and 24-day 
IV treatment for caspofungin in KSA, voriconazole had a considerable lower total 
treatment cost ($7,654) than LAMB ($16,564) and caspofungin ($17,362). Cost savings 
were primarily due to the lower drug cost, higher treatment efficacy, and shorter IV 
length-of-therapy associated with voriconazole. The cost advantage of voriconazole 
persists through a full-course of the first-line treatment with voriconazole IV (24 
days in KSA), even without oral treatment. ConClusions: This study suggests that 
voriconazole is cost-saving compared to LAMB and caspofungin in the treatment of 
IA from payer perspectives in KSA.
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a 
rare, progressive, debilitating and life-threatening neurodegenerative disease. 
Treatment for clinical symptoms of the disease is a priority. Although a rare dis-
ease, Portugal has the largest TTR-FAP foci in the world but data on treatment 
costs is lacking. The purpose of this study is to estimate the ambulatory medicines 
costs of TTR-FAP in Portugal. Methods: TTR-FAP patient’s medicines utilization 
